Andere Sprachen Alpha Tau Medical Ltd.

Aktien

A3DG50

IL0011839383

DRTS

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:55:08 20.05.2024			% 5 Tage	% 1. Jan.
2.83 ^USD	0.00%		+5.66%	-6.98%

06.05.	Alpha Tau präsentiert auf dem ESTRO-Kongress 2024 in Glasgow präklinische Daten, die einen abskopalen Immuneffekt in Tumormodellen der Bauchspeicheldrüse bei Mäusen belegen	CI
07.03.	Alpha Tau Medical Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer	13.05.
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer	13.05.
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	06.05.
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	06.05.
Alpha Tau to Participate in May Investor Conferences	01.05.
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit	25.03.
Alpha Tau Medical : to Present at the Jefferies Radiopharma Innovation Summit - Form 6-K	25.03.
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update	07.03.
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Alpha Tau Medical : Corporate Presentation – March 2024	04.03.
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference	26.02.
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference	20.12.
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference	20.12.
Alpha Tau to Participate in Sidoti Small-Cap Conference	29.11.
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	28.11.
Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	28.11.
Alpha Tau, HekaBio Seek Japan's Premarket Approval of Alpha-Radiation Therapy for Head, Neck Cancer	20.11.
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer	20.11.
Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer	20.11.
Alpha Tau Medical Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	16.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alpha Tau Medical Ltd.

Aktien

A3DG50

IL0011839383

DRTS

Andere Sprachen

Filter